0.07Open0.07Pre Close0 Volume4 Open Interest5.00Strike Price0.00Turnover154.60%IV43.14%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type-0.0460Delta0.0302Gamma123.86Leverage Ratio-0.0073Theta-0.0002Rho-5.70Eff Leverage0.0020Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet